Ruhlmann CH - Search Results

1

MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update.

Herrstedt J, Clark-Snow R, Ruhlmann CH, Jordan K, Scotté F. Herrstedt J, et al. Among authors: ruhlmann ch. Support Care Cancer. 2023 Dec 22;32(1):57. doi: 10.1007/s00520-023-08219-y. Support Care Cancer. 2023. PMID: 38135822 No abstract available.

2

[Pigs as an infection source for methicillin resistant Staphylococcus aureus infections in humans].

Ruhlmann CH, Kolmos HJ, Kristiansen JE, Skov R. Ruhlmann CH, et al. Ugeskr Laeger. 2008 Oct 20;170(43):3436. Ugeskr Laeger. 2008. PMID: 18976605 Danish.

3

Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann C, Herrstedt J. Ruhlmann C, et al. Ther Clin Risk Manag. 2009 Apr;5(2):375-84. doi: 10.2147/tcrm.s4026. Epub 2009 May 20. Ther Clin Risk Manag. 2009. PMID: 19536319 Free PMC article.

4

Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann C, Herrstedt J. Ruhlmann C, et al. Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48. doi: 10.1586/era.09.175. Expert Rev Anticancer Ther. 2010. PMID: 20131990 Review.

5

[Nausea and vomiting induced by antineoplastic therapy].

Petersen PC, Ruhlmann C, Herrstedt J. Petersen PC, et al. Ugeskr Laeger. 2019 Jul 1;181(27):V02190115. Ugeskr Laeger. 2019. PMID: 31267940 Free article. Review. Danish.

6

[Prophylaxis and treatment of radiation-induced nausea and vomiting].

Ruhlmann C, Petersen PC, Herrstedt J. Ruhlmann C, et al. Ugeskr Laeger. 2019 Aug 5;181(32):V02190116. Ugeskr Laeger. 2019. PMID: 31366424 Free article. Danish.

7

Response to Vitetta et al.

Nielsen SW, Ruhlmann CHB, Eckhoff L, Brønnum D, Herrstedt J, Dalton SO. Nielsen SW, et al. Support Care Cancer. 2022 Nov;30(11):8623-8624. doi: 10.1007/s00520-022-07356-0. Epub 2022 Sep 14. Support Care Cancer. 2022. PMID: 36100727 No abstract available.

8

2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.

Ruhlmann CH, Jordan K, Jahn F, Maranzano E, Molassiotis A, Dennis K. Ruhlmann CH, et al. Support Care Cancer. 2023 Dec 15;32(1):26. doi: 10.1007/s00520-023-08226-z. Support Care Cancer. 2023. PMID: 38097904 Free PMC article. Review.

9

2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.

Olver I, Clark-Snow R, Ruhlmann CH, Garcia-Del-Barrio MA, Schwartzberg L, Rapoport BL, Jahn F. Olver I, et al. Among authors: ruhlmann ch. Support Care Cancer. 2023 Dec 19;32(1):37. doi: 10.1007/s00520-023-08223-2. Support Care Cancer. 2023. PMID: 38110581

10

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.

Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ. Jordan K, et al. Among authors: ruhlmann ch. Support Care Cancer. 2023 Dec 22;32(1):53. doi: 10.1007/s00520-023-08220-5. Support Care Cancer. 2023. PMID: 38129530 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters